
Comprehension of Benefits vs. Risks: Fair Balance in DTC?



Ruth S. Day / Duke University

DTC Public Meeting FDA / DDMAC, November 1, 2005





How do people understand risk information?





How do people understand risk information?

ANSWER: With difficulty!





How do people understand risk information?

ANSWER: With difficulty!

WHY:

- -- Heavy information load
- -- Complex/technical information
- --etc.





How do people understand risk information?

ANSWER: With difficulty!

<u>WHY:</u>

- -- Heavy information load
- -- Complex/technical information
- --etc.




-- Cognitive IN-Accessibility

Cognitive Accessibility

The ease with which

Cognitive Accessibility


The ease with which



drug information

Cognitive Accessibility


The ease with which




drug information

in a safe and effective manner.


Cognitive IN-Accessibility






TYPES of INFORMATION





Rx Ads

Internet



Hardcopy



Professional Label


Patient Package Inserts


Medication Guides

Pharmacy Leaflets

Print Ads

OTC packages








- --Obtain quantitative measures
- --Calculate "cognitive accessibility"
- -- Compare benefits vs. risks

Cognitive Enhanced Cognitive Analyses Displays Experiments



- --Obtain quantitative measures
- --Calculate "cognitive accessibility"
- -- Compare benefits vs. risks



- --Same info
- --Based on cognitive principles

BASIC APPROACH

Cognitive Analyses



- --Obtain quantitative measures
- --Calculate "cognitive accessibility"
- -- Compare benefits vs. risks

Enhanced Displays



- --Same info
- --Based on cognitive principles


Cognitive Experiments

Test effects on:

- --Attention
- -- Comprehension
- -- Memory
- -- Problem Solving
- -- Decision Making
- --Behavior

BASIC APPROACH

Cognitive Analyses



- --Obtain quantitative measures
- --Calculate "cognitive accessibility"
- -- Compare benefits vs. risks

Enhanced Displays



- --Same info
- --Based on cognitive principles

Cognitive Experiments

Test effects on:

- --Attention
- --Comprehension
- --Memory
- -- Problem Solving
- -- Decision Making
- --Behavior

Health Outcomes

COGNITIVE PRINCIPLES

Information Load

Chunking

Coding

Representation

Location

Speed

Readability

Comprehension

Prior Knowledge

Attention


Cognitive Task

Metacognition


Rx TV Ads




Time Period




Experiments




Experiments









"What is it for?"





Overall





Rx TV Ads



Script

- --Benefits
- --Risks
- --etc.

Readability Z Comprehensibility

Readability Z Comprehensibility


However,

- --easy to measure
- --has predictive value
- --therefore = quick "proxy" for comprehensibility

2001


Rx Drug Ads


A lle g r a	Lipitor	Remicade	
A m bien	M eridia	Serevent	
Celebrex	Nasonex	Singulair	
Claritin	Orthotricyclen	Sonata	
Denavir	P a t a n o l	T a m iflu	
Diflucan	Paxil	V altre x	
Flonase	Pravacho1	Vioxx	
Flovent	Prevacid	W ellbutrin S R	
Im itre x	Prilosec	Zyrtec	
L a m i s i l	Procrit		
Ruth Day			




BENEFITS

SIDE EFFECTS







2005


Rx Drug Ads

Ambien	Lipitor	Procrit
Avodart	Lunesta	Restasis
Boniva	Nasonex	Singulair
Cialis	Nexium	Valtrex
Detrol-LA	OrthoEvra	Vesicare
Ditropan-XL	Orthotricyclen	Vytorin
Fosamax	Patanol	Welbutrin-XL
Humira	Plavix	Zelnorm
Imitrex	Premarin	Zyrtec


READABILITY

2001


2005



READABILITY




READABILITY




Averages 2001

READABILITY

2005











SideEff2

Harder 3

READABILITY Difference Score (B-SE)



READABILITY Difference Score (B-SE)



READABILITY Difference Score (B-SE) Prilosec Flonase Flovent am is il Meridia Singulair Sonata Claritin Jiflucan Im ifrex Lipitor Procrit em icade am iflu Valtrex Vioxx Serevent Denavif notricyclen Pravacho Wellbutrin SR elebre Vasonex

Fair

Balance?

Ruth Day

Benefit₃

Harder 2

No Diff 0

SideEff2

Harder 3

6

Am bien


READABILITY Difference Score (B-SE) Benefit₃ Harder 2 No Diff 0 Singulair Sonata Prilosec am is il am iffu Flomase Flovent Im ifrex Remicade ioxx Orthotricy clen Pravacho Dehavii SideEff2 Harder 3 Fair 6 Balance? Ruth Day


LOCATION of INFORMATION


SPEAKER TIMELINE




TIME (sec)










In clinical studies, less than 3% of people experienced drowsiness, cold or flu, nausea, or menstrual pain. Ask your doctor for more information about Allegra. And turn this allergy season into Allegra season. Enjoy your world.



In clinical studies, less than 3% of people experienced drowsiness, cold or flu, nausea, or menstrual pain. Ask your doctor for more information about Allegra. And turn this allergy season into Allegra season. Enjoy your world.

COGNITIVE PRINCIPLE

COGNITIVE PRINCIPLE: Serial Position Effect

Task: --see/hear list of items

--report them

COGNITIVE PRINCIPLE: Serial Position Effect


Task: --see/hear list of items

--report them


Typical Results:




2001 Location of Side Effects 30-sec. Ads




2001 Location of Side Effects 30-sec. Ads



2001 Location of Side Effects 45-sec. Ads



2001 Location of Side Effects 60-sec. Ads





Location of Side Effects

Unfavorable Unfavorable location


Location of Side Effects








Ruth Day



Ruth Day




Location of Risks

Unfavorable!

Location of Risks


Unfavorable!

- --What effect does location have on cognition?
- --Need evidence



Experimental TV Ad

Hypothetical Drug



Experimental TV Ad

Hypothetical Drug

Structure & content


- --Like typical ads
- --Purpose
 - --vary specific factors
 - -- observe effects on cognition

Experiment





Experiment







Experiment








Experiment





Same visual Same auditory

Differ only in location of side effects





Favorable UnFavorable LOCATION






Favorable UnFavorable LOCATION







Unable to Report Any Side Effects




Favorable UnFavorable LOCATION




Unable to ReportAny Side Effects




Favorable UnFavorable LOCATION




Unable to Report Any Side Effects





Favorable LOCATION





Actual TV Ads Specific Factors


















Divided Attention

Divided Attention

Nasonex



























WingFlaps




WingFlaps



WingFlaps + WingFlashes





Nasonex



- --WingFlaps
- --WingFlashes
- --Sparkly

Nasonex



- --WingFlaps
- --WingFlashes
- --Sparkly





Nasonex



- --WingFlaps
- --WingFlashes
- --Sparkly



- 2) Decreased knowledge
- 3) Comments

"There weren't any side effects."

Speaker Effects

Speaker Effects Typical Ad

Side effects

- --Spoken by narrator
- --Voice off-screen

New Approaches

My doctor said that headaches, diarrhea...



My doctor said that headaches, diarrhea ...

and abdominal pain ...



My doctor said that headaches, diarrhea ...

and abdominal pain ...





- --Chunking
- --Personalization
- --Positive affect



- 1) Increased knowledge
- 2) Acceptance
- 3) Comments

"They seem OK with the side effects."

... there are risks especially for some people



... there are risks especially for some people

...how do I know
I'm one of them?



... there are risks especially for some people

...how do I know
I'm one of them?







--Chunking

--Personalization --Positive Affect

--Attentive





- --Chunking
- --Personalization --Positive Affect
- --Attentive



- 1) Increased knowledge
- 2) Attentiveness
- 3) Acceptance




Factors

- --Readability
- --Location
- --Speed
- --Divided Attention
- --Speaker Effects
- --etc.

Conclusions


Current Practices

Unfair Balance



RISK INFORMATION

Physically present



Rush to judgment? Beware & Compare

Beware & Compare

Similar results

- --pharmacy leaflets
- --medication guides
- -- patient package inserts
- --product websites
- --professional label
- --OTC packages

Not just DTC!

Beware & Compare

Similar results

- --pharmacy leaflets
- --medication guides
- -- patient package inserts
- --product websites
- --professional label
- --OTC packages

1) Risk information

--less accessible than benefit info

Not just DTC!

Beware & Compare

Similar results

- --pharmacy leaflets
- --medication guides
- -- patient package inserts
- --product websites
- --professional label
- --OTC packages

1) Risk information

- --less accessible than benefit info
- 2) Risk performance
 - --worse

Not just DTC!

Beware & Compare

Similar results

- --pharmacy leaflets
- --medication guides
- -- patient package inserts
- --product websites
- --professional label
- --OTC packages

Not just DTC!

1) Risk information

--less accessible than benefit info

2) Risk performance

--worse

3) Risk performance


--increases with enhanced cognitive accessibility

Ruth Day

Recommendations

To Regulate or Not to Regulate (more)

THAT IS THE QUESTION



To Regulate or Not to Regulate (more)


THAT IS THE QUESTION

"Whether 'tis nobler in the mind to suffer The slings and arrows of inaccessible risks,

Or to take arms against a sea of troubles, And by opposing end them?"

--with apologies to William Shakespeare....

Should there be an end to DTC?



Should there be an end to DTC?

Pros Cons

This research

- 1) Unfair balance of benefits vs. risks
- 2) But it can be improved
- 3) Better balance -- improved performance
 - --perception
 - --comprehension
 - --memory

Evidence-based Approach Industry Regulatory

Evidence-based Approach

Positive Treatment

Benefits Risks

Location
Speed
Competing
information




(etc.)

Evidence-based Approach

Positive Treatment

Location
Speed
Competing
information

(etc.)






















Comprehension of Benefits vs. Risks: Fair Balance in DTC?



ruthday@duke.edu

http://www.duke.edu/~ruthday/medcog.html